Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I notice from the prospectus that Allan Syms will work 3 days per week as Chief Exec, but Professor Cleverley is only contracted as a NED for 20 days per year.
Does this indicate that the clinical design is pretty much complete and that Allan Syms role will be to obtain the relevant approvals with input from Prof Cleverley as required ?
I will put this forward as a question for the webinar
Let's keep the positive and informative posts coming, there is a Q & A webinar on the 6th May, so let's start thinking about what questions to ask.
Aspen
Some questions from me, but feel free to ask them in the Webinar if i am not around and keep adding other questions to the list:
1-Are there any more experiments to be carried out to validate this test?
2-How far are we from commercialisation? are we currently in discussion with a partner? what happened to the old partner (Fuijirebio Diagnostics)?
3-When are we applying for CE marking and FDA approval (as mentioned in the prospectus)?
4-where do you see the company and the sp in 6months and 1 year from from now (bit too direct) but important for us as investors.
5-Can he/or the company do an investors interview through the usual channels (proactive investors etc..) and keep us updated especially in the first few weeks, a good PR is essential for any new company.
Marko/Wideglide, one bit of advice..... buy low, sell high..... puts you in a much better position with your stocks.... KR BC
Tra1
You have set the ball rolling with 5 very good questions.
Aspen
Question 6. Another cheeky one.
The prospectus mentions an anticipated kit cost to the NHS of £200 ea. Market potential of circa £20m p.a. Plus a USA revenue of $115m p.a .
Is there a target net margin for this combined revenue?
ATB LB
Should read ** sales margin **
And make it Q7. ;)
Question 7. Is Allan going to step down from his current role and be full-time in this?